| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30.
|
| [2] |
Feng RM, Zong YN, Cao SM, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?[J]. Cancer Commun, 2019, 39(1): 22.
|
| [3] |
Jia X, Du P, Wu K, et al. Pancreatic cancer mortality in China: characteristics and prediction[J]. Pancreas, 2018, 47(2): 233-237.
|
| [4] |
Egawa S, Toma H, Ohigashi H, et al. Japan pancreatic cancer registry; 30th year anniversary: Japan Pancreas Society[J]. Pancreas, 2012, 41(7): 985-992.
|
| [5] |
Tummers WS, Groen JV, Sibinga Mulder BG, et al. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery[J]. Br J Surg, 2019, 106(8): 1055-1065.
|
| [6] |
Ghaneh P, Kleeff J, Halloran CM, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma[J]. Ann Surg, 2019, 269(3): 520-529.
|
| [7] |
Imamura M, Doi R, Imaizumi T, et al. A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer[J]. Surgery, 2004, 136(5): 1003-1011.
|
| [8] |
Doi R, Imamura M, Hosotani R, et al. Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial[J]. Surg Today, 2008, 38(11): 1021-1028.
|
| [9] |
杨尹默，李佶松. 局部进展期胰腺癌综合治疗的现状与进展[J]. 中华消化外科杂志, 2017, 16(10): 979-982.
|
| [10] |
Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
|
| [11] |
Delpero JR, Sauvanet A. Vascular resection for pancreatic cancer: 2019 French recommendations based on a literature review from 2008 to 6-2019[J]. Front Oncol, 2020, 10: 40.
|
| [12] |
中国抗癌协会胰腺癌专业委员会. 胰腺癌综合诊治指南(2018版) [J]. 临床肝胆病杂志, 2018, 34(10): 2109-2120.
|
| [13] |
Pindak D, Tomas M, Dolnik J, et al. Morbidity, mortality and long term survival in patients with vascular resection in pancreatic cancer - single center experience[J]. Neoplasma, 2017, 64(3): 460-463.
|
| [14] |
Kasumova GG, Conway WC, Tseng JF. The role of venous and arterial resection in pancreatic cancer surgery[J]. Ann Surg Oncol, 2018, 25(1): 51-58.
|
| [15] |
Network. NCC. (NCCN) Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma, Version 1.2020. 2019 [cited]Available from: https://www.nccn.org/professionals/physician_gls/default.aspx
|
| [16] |
Nakao A, Takeda S, Inoue S, et al. Indications and techniques of extended resection for pancreatic cancer[J]. World J Surg, 2006, 30(6): 976-982; discussion 983-974.
|
| [17] |
Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)[J]. Surgery, 2014, 155(6): 977-988.
|
| [18] |
Shibata C, Kobari M, Tsuchiya T, et al. Pancreatectomy combined with superior mesenteric-portal vein resection for adenocarcinoma in pancreas[J]. World J Surg, 2001, 25(8): 1002-1005.
|
| [19] |
Ishikawa O, Ohigashi H, Imaoka S, et al. Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein[J]. Ann Surg, 1992, 215(3): 231-236.
|
| [20] |
Khaladj N, Pichlmaier U, Stachmann A, et al. Cryopreserved human allografts (homografts) for the management of graft infections in the ascending aortic position extending to the arch[J]. Eur J Cardiothorac Surg, 2013, 43(6): 1170-1175.
|
| [21] |
Veal A, Oshin O, Schober M, et al. Cryopreserved superficial femoral artery homografts for aortoiliac segment replacement in infection[J]. Vascular, 2014, 22(1): 65-67.
|
| [22] |
Zhu J, Li X, Kou J, et al. Proposed Chaoyang vascular classification for superior mesenteric-portal vein invasion, resection, and reconstruction in patients with pancreatic head cancer during pancreaticoduodenectomy - A retrospective cohort study[J]. Int J Surg, 2018, 53: 292-297.
|
| [23] |
Huang J, Wang H, Fan ST, et al. The national program for deceased organ donation in China[J]. Transplantation, 2013, 96(1): 5-9.
|
| [24] |
Medicine OCfE-b. Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009). 2009 [cited]Available from: https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
|
| [25] |
Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies[J]. BMJ, 2008, 336(7653): 1106-1110.
|
| [26] |
Yekebas EF, Bogoevski D, Cataldegirmen G, et al. En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients[J]. Ann Surg, 2008, 247(2): 300-309.
|
| [27] |
Flis V, Potrc S, Kobilica N, et al. Pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head with venous resection[J]. Radiol Oncol, 2016, 50(3): 321-328.
|
| [28] |
Hayasaki A, Isaji S, Kishiwada M, et al. Survival analysis in patients with pancreatic ductal adenocarcinoma undergoing chemoradiotherapy followed by surgery according to the international consensus on the 2017 definition of borderline resectable cancer[J]. Cancers (Basel), 2018, 10(3): 65.
|
| [29] |
Leach SD, Lee JE, Charnsangavej C, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head[J]. Br J Surg, 1998, 85(5): 611-617.
|
| [30] |
郎韧，吕少诚，贺强. 伴有门静脉系统侵犯的胰腺癌外科治疗[J]. 中华肝胆外科杂志, 2020, 26(11): 801-804.
|
| [31] |
范顺利，姜涛，潘飞, 等. 分支异体血管置换对胰腺癌术后患者左侧区域性门脉高压的预防作用[J]. 中华肝胆外科杂志, 2019, 25(5): 367-370.
|
| [32] |
吕少诚，贺强，郎韧, 等. 异体血管置换技术在合并血管侵犯的胰腺癌根治性手术中的应用[J]. 中华外科杂志, 2018, 56(4): 274-278.
|
| [33] |
Jashari R, Van Hoeck B, Ngakam R, et al. Banking of cryopreserved arterial allografts in Europe: 20 years of operation in the European Homograft Bank (EHB) in Brussels[J]. Cell Tissue Bank, 2013, 14(4): 589-599.
|
| [34] |
Jashari R, Goffin Y, Vanderkelen A, et al. European homograft bank: twenty years of cardiovascular tissue banking and collaboration with transplant coordination in Europe[J]. Transplant Proc, 2010, 42(1): 183-189.
|
| [35] |
Kadner A, Chen RH, Mitchell RN, et al. Hemograft crossmatching is unnecessary due to the absence of blood group antigens[J]. Ann Thorac Surg, 2001, 71(5 Suppl): S349-S352.
|
| [36] |
Heng WL, Madhavan K, Wee P, et al. Banking of cryopreserved iliac artery and vein homografts: clinical uses in transplantation[J]. Cell Tissue Bank, 2015, 16(2): 235-242.
|
| [37] |
Tabaku M, Jashari R, Carton HF, et al. Processing of cardiovascular allografts: effectiveness of European Homograft Bank (EHB) antimicrobial treatment (cool decontamination protocol with low concentration of antibiotics)[J]. Cell Tissue Bank, 2004, 5(4): 261-266.
|
| [38] |
史源. 欧洲同种移植物组织库(EHB)参观见闻[J/CD]. 实用器官移植电子杂志, 2016, 4(2): 128.
|
| [39] |
Mabrut JY, Abdullah SS, Rode A, et al. Cryopreserved iliac artery allograft for primary arterial revascularization in adult liver transplantation[J]. Clin Transplant, 2012, 26(1): E12-E16.
|
| [40] |
Corner JA, Berwanger CS, Stansby G. Preservation of vascular tissue under hypothermic conditions[J]. J Surg Res, 2003, 113(1): 21-25.
|
| [41] |
Ma Y, Li Q, Ye ZM, et al. Use of arterial conduit for arterial revascularization during liver and multivisceral transplantation[J]. Chin Med J (Engl), 2011, 124(19): 2986-2989.
|
| [42] |
van Doormaal TP, Sluijs JH, Vink A, et al. Comparing five simple vascular storage protocols[J]. J Surg Res, 2014, 192(1): 200-205.
|
| [43] |
Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer[J]. Lancet Oncol, 2019, 20(10): e566-e581.
|
| [44] |
Thein KZ, Oo TH. 2019 international clinical practice guidelines for the treatment of venous thromboembolism[J]. Lancet Oncol, 2019, 20(12): e655.
|
| [45] |
Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update[J]. J Clin Oncol, 2020, 38(5): 496-520.
|
| [46] |
Chen LT, Martinelli E, Cheng AL, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: A TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO[J]. Ann Oncol, 2020, 31(3): 334-351.
|